The Role of Glutamate Underlying Treatment-resistant Depression

키워드

참고문헌 (136)

1. Selye H, "A syndrome produced by diverse nocuous agents. 1936", J Neuropsychiatry Clin Neurosci, 10, pp.230~231 (1998)
2. McEwen BS, "Stress-and allostasis-induced brain plasticity", Annu Rev Med, 62, pp.431~445 (2011)
3. Duman RS, "Synaptic plasticity and depression : New insights from stress and rapid-acting antidepressants", Nat Med, 22, pp.238~249 (2016)
4. Wonsuk Choi, "Interactive Effects of Serum Leptin Levels and Physical Comorbidity on the Pharmacotherapeutic Response of Depressive Disorders", Clinical Psychopharmacology and Neuroscience, 20(4), pp.662~674 (2022), 대한정신약물학회[DOI]
5. Bagot RC, "Ketamine and imipramine reverse transcriptional signatures of susceptibility and induce resilience-specific gene expression profiles", Biol Psychiatry, 81, pp.285~295 (2017)
6. Akil H, "Treatment resistant depression : A multi-scale, systems biology approach", Neurosci Biobehav Rev, 84, pp.272~288 (2018)
7. Sanacora G, "Towards a glutamate hypothesis of depression : An emerging frontier of neuropsychopharmacology for mood disorders", Neuropharmacology, 62, pp.63~77 (2012)
8. Bunney WE Jr, "Norepinephrine in depressive reactions. A review", Arch Gen Psychiatry, 13, pp.483~494 (1965)
9. Schildkraut JJ, "The catecholamine hypothesis of affective disorders : A review of supporting evidence", Am J Psychiatry, 122, pp.509~522 (1965)
10. Gaynes BN, "What did STAR*D teach us? Results from a largescale, practical, clinical trial for patients with depression", Psychiatr Serv, 60, pp.1439~1445 (2009)
11. Rush AJ, "Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : A STAR*D report", Am J Psychiatry, 163, pp.1905~1917 (2006)
12. Conway CR, "Toward an evidence-based, operational definition of treatment-resistant depression : When enough is enough", JAMA Psychiatry, 74, pp.9~10 (2017)
13. Corral R, "Suicidality and quality of life in treatment-resistant depression patients in Latin America : Secondary interim analysis of the TRAL study", Front Psychiatry, 13, pp.812938~ (2022)
14. Fabbri C, "Drug repositioning for treatment-resistant depression : Hypotheses from a pharmacogenomic study", Prog Neuropsychopharmacol Biol Psychiatry, 104, pp.110050~ (2021)
15. Sheng Min Wang, "Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis", Clinical Psychopharmacology and Neuroscience, 19(2), pp.341~354 (2021), 대한정신약물학회[DOI]
16. Moda-Sava RN, "Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation", Science, 364, pp.eaat8078~ (2019)
17. Zhou YL, "Volumetric changes in subcortical structures following repeated ketamine treatment in patients with major depressive disorder : A longitudinal analysis", Transl Psychiatry, 10, pp.264~ (2020)
18. Sydnor VJ, "Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine’s antidepressant effects", Transl Psychiatry, 10, pp.432~ (2020)
19. Gill H, "The effects of ketamine on cognition in treatment-resistant depression : A systematic review and priority avenues for future research", Neurosci Biobehav Rev, 120, pp.78~85 (2021)
20. Rasmussen N, "Making the first anti-depressant : Amphetamine in American medicine, 1929-1950", J Hist Med Allied Sci, 61, pp.288~323 (2006)
21. Kauffman GB, "The discovery of iproniazid and its role in antidepressant therapy", J Chem Educ, 56, pp.35~ (1979)
22. Axelrod J, "Noradrenaline : Fate and control of its biosynthesis", Science, 173, pp.598~606 (1971)
23. Yochelson S, "Isocarboxazid in the treatment of depression", J Clin Exp Psychopathol Q Rev Psychiatry Neurol, 21, pp.196~204 (1960)
24. Agin HV, "Tranylcypromine in depression : A clinical report", Am J Psychiatry, 117, pp.150~151 (1960)
25. Bogdanski DF, "The distribution of serotonin, 5-hydroxytryptophan decarboxylase, and monoamine oxidase in brain", J Neurochem, 1, pp.272~278 (1957)
26. Schayer RW, "Role of monoamine oxidase in nor-adrenaline metabolism", Am J Physiol, 182, pp.285~286 (1955)
27. Gillman PK, "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated", Br J Pharmacol, 151, pp.737~748 (2007)
28. Dua D, "Imipramine in schizophrenia with depressive symptomatology", Indian J Psychiatry, 32, pp.229~234 (1990)
29. Pletscher A, "The discovery of antidepressants : A winding path", Experientia, 47, pp.4~8 (1991)
30. Endler NS, "The origins of electroconvulsive therapy(ECT)", Convuls Ther, 4, pp.5~23 (1988)
31. Blackwell B, "Hypertensive crisis due to monoamine-oxidase inhibitors", Lancet, 2, pp.849~850 (1963)
32. Zeller EA, "In vivo inhibition of liver and brain monoamine oxidase by 1-Isonicotinyl-2-isopropyl hydrazine", Proc Soc Exp Biol Med, 81, pp.459~461 (1952)
33. Glowinski J, "Inhibition of uptake of tritiated-noradrenaline in the intact rat brain by imipramine and structurally related compounds", Nature, 204, pp.1318~1319 (1964)
34. Schildkraut JJ, "Norepinephrine metabolism and drugs used in the affective disorders : A possible mechanism of action", Am J Psychiatry, 124, pp.600~608 (1967)
35. Moncrieff J, "The serotonin theory of depression : A systematic umbrella review of the evidence", Mol Psychiatry (2022)[DOI]
36. Ashcroft GW, "5-hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases", Lancet, 2, pp.1049~1052 (1966)
37. Lisciani R, "Comparative cardiovascular toxicity of trazodone and imipramine in the rat", Arch Toxicol Suppl, pp.169~172 (1978)
38. Wong DT, "Kinetics of serotonin accumulation into synaptosomes of rat brain--effects of amphetamine and chloroamphetamines", Biochem Pharmacol, 22, pp.311~322 (1973)
39. Wong DT, "Case history : The discovery of fluoxetine hydrochloride(Prozac)", Nat Rev Drug Discov, 4, pp.764~774 (2005)
40. Laporta M, "Hypomania induced by sertraline, a new serotonin reuptake inhibitor", Am J Psychiatry, 144, pp.1513~1514 (1987)
41. Gottlieb P, "Initial, clinical trial of a new, specific 5-HT reuptake inhibitor, citalopram(Lu 10-171)", Acta Psychiatr Scand, 62, pp.236~244 (1980)
42. Stahl SM, "A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor", Prim Care Companion J Clin Psychiatry, 6, pp.159~166 (2004)
43. Rothmore J, "Antidepressant-induced sexual dysfunction", Med J Aust, 212, pp.329~334 (2020)
44. Khan A, "Venlafaxine in depressed outpatients", Psychopharmacol Bull, 27, pp.141~144 (1991)
45. Asnis GM, "Efficacy and safety of levomilnacipran sustained release 40mg, 80 mg, or 120 mg in major depressive disorder : A phase 3, randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 74, pp.242~248 (2013)
46. Fuller RW, "Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice", J Pharmacol Exp Ther, 269, pp.132~136 (1994)
47. Machado M, "Comparison of SSRIs and SNRIs in major depressive disorder : A meta-analysis of head-to-head randomized clinical trials", J Clin Pharm Ther, 35, pp.177~188 (2010)
48. Ramic E, "Assessment of the antidepressant side effects occurrence in patients treated in primary care", Mater Sociomed, 32, pp.131~134 (2020)
49. Krystal JH, "Ketamine : A paradigm shift for depression research and treatment", Neuron, 101, pp.774~778 (2019)
50. Weston PG, "Magnesium as a sedative", Am J Psychiatry, 78, pp.637~638 (1922)
51. Watkins JC, "The glutamate story", Br J Pharmacol, 147(Suppl 1), pp.S100~S108 (2006)
52. Orrego F, "The chemical nature of the main central excitatory transmitter : A critical appraisal based upon release studies and synaptic vesicle localization", Neuroscience, 56, pp.539~555 (1993)
53. Waagepetersen HS, "Handbook of neurochemistry and molecular neurobiology: Amino acids and peptides in the nervous system", pp.1~21 (2007), Springer US
54. Kew JN, "Ionotropic and metabotropic glutamate receptor structure and pharmacology", Psychopharmacology (Berl), 179, pp.4~29 (2005)
55. Berman RM, "Antidepressant effects of ketamine in depressed patients", Biol Psychiatry, 47, pp.351~354 (2000)
56. Zarate CA Jr, "A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression", Arch Gen Psychiatry, 63, pp.856~864 (2006)
57. Zarate CA Jr, "Replication of ketamine’s antidepressant efficacy in bipolar depression : A randomized controlled add-on trial", Biol Psychiatry, 71, pp.939~946 (2012)
58. Zarate CA Jr, "Cellular plasticity cascades : Targets for the development of novel therapeutics for bipolar disorder", Biol Psychiatry, 59, pp.1006~1020 (2006)
59. Kim J, "Metabotropic glutamate receptor 5 in amygdala target neurons regulates susceptibility to chronic social stress", Biol Psychiatry, 92, pp.104~115 (2022)
60. Koo JW, "Role of mesolimbic brain-derived neurotrophic factor in depression", Biol Psychiatry, 86, pp.738~748 (2019)
61. Krishnan V, "Animal models of depression : Molecular perspectives", Curr Top Behav Neurosci, 7, pp.121~147 (2011)
62. Planchez B, "Animal models of major depression: Drawbacks and challenges", J Neural Transm(Vienna), 126, pp.1383~1408 (2019)
63. Katz RJ, "Animal model of depression : Pharmacological sensitivity of a hedonic deficit", Pharmacol Biochem Behav, 16, pp.965~968 (1982)
64. Koo JW, "IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress", Proc Natl Acad Sci U S A, 105, pp.751~756 (2008)
65. Koo JW, "Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior", Proc Natl Acad Sci U S A, 107, pp.2669~2674 (2010)
66. Surget A, "Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal", Biol Psychiatry, 64, pp.293~301 (2008)
67. Caldarone BJ, "Rodent models of treatment-resistant depression", Eur J Pharmacol, 753, pp.51~65 (2015)
68. Jayatissa MN, "Hippocampal cytogenesis correlates to escitalopram-mediated recovery in a chronic mild stress rat model of depression", Neuropsychopharmacology, 31, pp.2395~2404 (2006)
69. Bisgaard CF, "Proteomic investigation of the ventral rat hippocampus links DRP-2 to escitalopram treatment resistance and SNAP to stress resilience in the chronic mild stress model of depression", J Mol Neurosci, 32, pp.132~144 (2007)
70. Nieto-Gonzalez JL, "Presynaptic plasticity as a hallmark of rat stress susceptibility and antidepressant response", PLoS One, 10, pp.e0119993~ (2015)
71. Wang Y, "Quetiapine add-on therapy improves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats", Behav Brain Res, 253, pp.206~211 (2013)
72. Fumagalli F, "Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801", Neuroreport, 15, pp.2109~2112 (2004)
73. Kamel LY, "Vagus nerve stimulation : An update on a novel treatment for treatment-resistant depression", J Neurol Sci, 434, pp.120171~ (2022)
74. Wang JY, "Mechanisms underlying antidepressant effect of transcutaneous auricular vagus nerve stimulation on CUMS model rats based on hippocampal a7nAchR", NF-kB signal pathway, 2021, pp.18, 291~
75. Bambico FR, "Neuroplasticity-dependent and-independent mechanisms of chronic deep brain stimulation in stressed rats", Transl Psychiatry, 5, pp.e674~ (2015)
76. Garcia LS, "Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats", Prog Neuropsychopharmacol Biol Psychiatry, 33, pp.450~455 (2009)
77. Duman RS, "Synaptic dysfunction in depression : Potential therapeutic targets", Science, 338, pp.68~72 (2012)
78. Der-Avakian A, "Enduring deficits in brain reward function after chronic social defeat in rats : Susceptibility, resilience, and antidepressant response", Biol Psychiatry, 76, pp.542~549 (2014)
79. McMakin DL, "Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression", J Am Acad Child Adolesc Psychiatry, 51, pp.404~411 (2012)
80. Lopez JP, "Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2", Neuron, 110, pp.2283~2298 (2022)
81. Yang C, "Mechanistic target of rapamycin-independent antidepressant effects of(R)-ketamine in a social defeat stress model", Biol Psychiatry, 83, pp.18~28 (2018)
82. Davies SN, "Ketamine blocks an NMDA receptor-mediated component of synaptic transmission in rat hippocampus in a voltage-dependent manner", Neurosci Lett, 92, pp.213~217 (1988)
83. Domino EF, "History and pharmacology of PCP and PCP-related analogs", J Psychedelic Drugs, 12, pp.223~227 (1980)
84. Denomme N, "The Domino effect : Ed Domino’s early studies of psychoactive drugs", J Psychoactive Drugs, 50, pp.298~305 (2018)
85. Parke Davis, "Ketamine hydrochloride(Ketalar)", Clin Pharmacol Ther, 11, pp.777~780 (1970)
86. White PF, "Comparative pharmacology of the ketamine isomers. Studies in volunteers", Br J Anaesth, 57, pp.197~203 (1985)
87. Daly EJ, "Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression : A randomized clinical trial", JAMA Psychiatry, 75, pp.139~148 (2018)
88. Cristea IA, "US Food and Drug Administration approval of esketamine and brexanolone", Lancet Psychiatry, 6, pp.975~977 (2019)
89. "Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression" (2021)[URL]
90. Yang C, "R-ketamine : A rapid-onset and sustained antidepressant without psychotomimetic side effects", Transl Psychiatry, 5, pp.e632~ (2015)
91. Anis NA, "The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate", Br J Pharmacol, 79, pp.565~575 (1983)
92. Thomson AM, "An N-methylaspartate receptor-mediated synapse in rat cerebral cortex : A site of action of ketamine?", Nature, 313, pp.479~481 (1985)
93. Trullas R, "Functional antagonists at the NMDA receptor complex exhibit antidepressant actions", Eur J Pharmacol, 185, pp.1~10 (1990)
94. Omranifard V, "Memantine add on to citalopram in elderly patients with depression : A double-blind placebo-controlled study", J Res Med Sci, 19, pp.525~530 (2014)
95. Moghaddam B, "Activation of glutamatergic neurotransmission by ketamine : A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex", J Neurosci, 17, pp.2921~2927 (1997)
96. Xi D, "Dizocilpine(MK-801)induces distinct changes of N-methyl-D-aspartic acid receptor subunits in parvalbumin-containing interneurons in young adult rat prefrontal cortex", Int J Neuropsychopharmacol, 12, pp.1395~1408 (2009)
97. Widman AJ, "Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy", Proc Natl Acad Sci U S A, 115, pp.E3007~E3016 (2018)
98. Khlestova E, "The role of GluN2C-containing NMDA receptors in ketamine’s psychotogenic action and in schizophrenia models", J Neurosci, 36, pp.11151~11157 (2016)
99. Zanos P, "A negative allosteric modulator for a5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in mice", eNeuro, 4 (2017)
100. Ren Z, "Bidirectional homeostatic regulation of a depression-related brain state by gamma-aminobutyric acidergic deficits and ketamine treatment", Biol Psychiatry, 80, pp.457~468 (2016)
101. Fuchs T, "Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state", Mol Psychiatry, 22, pp.920~930 (2017)
102. Fredj NB, "A resting pool of vesicles is responsible for spontaneous vesicle fusion at the synapse", Nat Neurosci, 12, pp.751~758 (2009)
103. Autry AE, "NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses", Nature, 475, pp.91~95 (2011)
104. Kavalali ET, "Targeting homeostatic synaptic plasticity for treatment of mood disorders", Neuron, 106, pp.715~726 (2020)
105. Miller OH, "GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine", Elife, 3, pp.e03581~ (2014)
106. Guo H, "Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice", Hum Mol Genet, 12, pp.2519~2532 (2003)
107. Li N, "mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists", Science, 329, pp.959~964 (2010)
108. Maeng S, "Cellular mechanisms underlying the antidepressant effects of ketamine : Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors", Biol Psychiatry, 63, pp.349~352 (2008)
109. Gould TD, "Molecular pharmacology and neurobiology of rapid-acting antidepressants", Annu Rev Pharmacol Toxicol, 59, pp.213~236 (2019)
110. Zarate CA Jr, "A double-blind, placebo-controlled study of memantine in the treatment of major depression", Am J Psychiatry, 163, pp.153~155 (2006)
111. Kishi T, "A meta-analysis of memantine for depression", J Alzheimers Dis, 57, pp.113~121 (2017)
112. Zanos P, "NMDAR inhibition-independent antidepressant actions of ketamine metabolites", Nature, 533, pp.481~486 (2016)
113. Zanos P, "Ketamine and ketamine metabolite pharmacology : Insights into therapeutic mechanisms", Pharmacol Rev, 70, pp.621~660 (2018)
114. Zanos P, "Mechanisms of ketamine action as an antidepressant", Mol Psychiatry, 23, pp.801~811 (2018)
115. Vyklicky V, "Structure, function, and pharmacology of NMDA receptor channels", Physiol Res, 63(Suppl 1), pp.S191~S203 (2014)
116. Machado-Vieira R, "New targets for rapid antidepressant action", Prog Neurobiol, 152, pp.21~37 (2017)
117. Nosyreva E, "Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade", Front Mol Neurosci, 7, pp.94~ (2014)
118. Jourdi H, "Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation", J Neurosci, 29, pp.8688~8697 (2009)
119. Aguilar-Valles A, "Antidepressant actions of ketamine engage cell-specific translation via eIF4E", Nature, 590, pp.315~319 (2021)
120. Zanos P, "(2R, 6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions", Proc Natl Acad Sci U S A, 116, pp.6441~6450 (2019)
121. Fukumoto K, "The antidepressant effects of an mGlu2", 3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN, 2016, pp.41, 1046~1056
122. Lähteenvuo M, "Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare : A nationwide cohort study", J Affect Disord, 308, pp.236~242 (2022)
123. Gronemann FH, "Treatment patterns in patients with treatment-resistant depression in Danish patients with major depressive disorder", J Affect Disord, 287, pp.204~213 (2021)
124. Salk RH, "Gender differences in depression in representative national samples : Meta-analyses of diagnoses and symptoms", Psychol Bull, 143, pp.783~822 (2017)
125. Kornstein SG, "Gender differences in treatment response to sertraline versus imipramine in chronic depression", Am J Psychiatry, 157, pp.1445~1452 (2000)
126. Sigtermans M, "S(+)-ketamine effect on experimental pain and cardiac output : A population pharmacokinetic-pharmacodynamic modeling study in healthy volunteers", Anesthesiology, 111, pp.892~903 (2009)
127. Freeman MP, "Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression", J Psychiatr Res, 110, pp.166~171 (2019)
128. Rybakowski JK, "Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression", Int J Psychiatry Clin Pract, 21, pp.99~103 (2017)
129. Sarkar A, "Sex differences in effects of ketamine on behavior, spine density, and synaptic proteins in socially isolated rats", Biol Psychiatry, 80, pp.448~456 (2016)
130. Carrier N, "Sex differences in the antidepressantlike effects of ketamine", Neuropharmacology, 70, pp.27~34 (2013)
131. Saland SK, "Hedonic sensitivity to low-dose ketamine is modulated by gonadal hormones in a sex-dependent manner", Sci Rep, 6, pp.21322~ (2016)
132. Phillips JL, "Single, repeated, and maintenance ketamine infusions for treatment-resistant depression : A randomized controlled trial", Am J Psychiatry, 176, pp.401~409 (2019)
133. Bartova L, "Sex-related effects in major depressive disorder : Results of the European Group for the Study of Resistant Depression", Depress Anxiety, 38, pp.896~906 (2021)
134. Aswal N, "Study on antidepressant drug to cure depression", J Formul Sci Bioavailab, 2, pp.1000121~ (2018)
135. Martín-Hernández D, "The neuroscience of depression", pp.345~355 (2021), Academic Press
136. Pham TH, "Fast-acting antidepressant activity of ketamine : Highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies", Pharmacol Ther, 199, pp.58~90 (2019)

관련 논문AI추천